

Bod Australia becomes one of the first ASX listed companies to be granted a medicinal cannabis import licence.

- **Import licence granted for medicinal cannabis products**
- **Licence will allow the import of Linnea's unique phyto-complex cannabis extracts for multiple commercial and clinical applications**
- **Key catalyst for sale of finished goods and commencement of Phase I Clinical trials**

Sydney, Australia – 4 December 2017: Developer and distributor of natural, evidence-based cosmetics and natural medicines Bod Australia Limited ("Bod" or the "Company") (ASX: BDA) is pleased to advise that it has been granted an import licence for medicinal cannabis products.

The licence, granted through the NSW Department of Health and the Therapeutic Goods Administration, allows for the, storage and supply of medicinal cannabis. Following permission to import from the Office of Drug Control (ODC), Product will be available to authorised prescribers and for Bod's clinical trial programs. According to the ODC website Bod is one of the first ASX listed companies to be granted a licence to import medicinal cannabis.

Bod will now begin the process for approval through the Federal ODC to import a range of cannabis products from overseas producers including oils and raw materials from exclusive partner, Linnea SA. This will be in the form of finished goods for immediate commercial purposes and for use in clinical trials.

Linnea is a manufacturer of medicinal cannabis extracts, botanical and pharmaceutical ingredients and finished goods for use in the pharmaceutical, nutraceutical and cosmetic industries. Based in Switzerland, Linnea has been operating for over 35 years and is owned by two large European companies – Ipsen and Schwabe.

Linnea's industry-leading standardised phyto-complex cannabis extracts are internationally renowned for having very low THC concentrations (less than 0.05%). In addition, Linnea are able to preserve the cannabinoid and phytocomplex profiles of the plant – producing a unique extract that has a standardised and consistent chemical profile.

This is a significant and material development for Bod and marks a key step in the Company establishing their medicinal cannabis operations in Australia and growing revenues from the sale of the therapeutic goods and extracts.

The Company expects to generate near term revenues from the sales of cannabis oils, which will be available for patients through physicians authorised to prescribe medicinal cannabis under Special Access Category B. There are currently a growing number of physicians licenced to prescribe medicinal cannabis in Australia and Bod looks forward to working with them in the future.

Further to receiving the licence and relative approvals, the Company will finalise a product for their Phase I Clinical trial scheduled to begin in 2018. The Phase I trial aims to assess the safety, tolerability and pharmacokinetics of a proprietary sublingual formulation of the unique Linnea phytocomplex cannabis extract. The results of this trial will assist to lead to the development of specific therapeutic indications for Bod's medicinal cannabis product suite. The Company is currently finalising the Phase I Clinical trial program and will update shareholders on these developments shortly.

In addition, the licence and related research trials enable Bod to develop cannabis based products and materials for potential export markets in Asia as part of a broader distribution strategy.

Bod Australia CEO Jo Patterson said: "Receiving an import licence is a great achievement for Bod Australia and delivers significant value. It is a game changer in establishing medicinal cannabis operations in Australia.

For personal use only

“In order to move to an environment which we generate sales from this part of our business, we will sell our Cannabis Oil through approved prescribers under the Special Access Category B scheme. We will also commence our research and development to develop a unique product for our clinical trials.

“The Company is currently investigating ways in which we can advance our Phase I Clinical Trial design to reduce time to market and cost savings, and look forward to updating shareholders as this progresses. We are also undertaking discussions around the production of a patented and unique delivery method for our trial and are pleased to say that these are well advanced. We anticipate further updates on this front in the near future.”

For more information: bodaustralia.com

- ENDS -

About Bod Australia

Bod Australia Limited operates a cosmetics and natural medicines business focused on all natural, evidence based products. In the cosmetics segment Bod has exclusive rights to distribute Pommade Divine in Australia, New Zealand and the export market to China, and BIOEFFECT in Australia and New Zealand. Bod is also developing a range of natural medicines, having recently commenced sales of Pinpoint, for memory and concentration, and natural anti-inflammatory Flexofytol. Led by an experienced sales team which includes ex-Bellamy’s sales representatives, the Company is focused on the distribution of these brands and intends to develop new products across baby skin care and additional natural remedies targeting menopause and sinusitis. Bod has also signed a supply agreement with Swiss botanical extracts manufacturer Linnea Natural Pharma Solutions to develop skin care and therapeutic products using standardised, GMP-certified cannabis extracts.

For more information please contact:

Jo Patterson
Bod Australia
+61 2 9199 5018

Henry Jordan – Six Degrees Investor Relations
Henry.jordan@sdir.com.au
+61 431 271 538

For personal use only